在具有各种CDKN2A突变状态的原发性多种和家族性黑色素瘤中CD8-淋巴细胞表型的重要性
Luana-Andreea Boşoteanu1,2, Emma Gheorghe3,4, Mariana Aşchie5,6,7
1Department of Dermatovenerology, "Elias" Emergency University Hospital, 011461 Bucharest, Romania.
Medicina (Kaunas, Lithuania)
|December 23, 2023
概括
人工智能 (AI) 软件比手动计数更准确地量化了黑色素瘤中CD8阳性瘤透淋巴细胞 (TILs). 较高的CD8+TIL与转移部位的增加相关,有助于黑色素瘤的预后.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 计算病理学计算病理学
背景情况:
- 黑色素瘤的发病率,特别是皮肤和粘膜类型,正在上升.
- 在家族性和多重原发性黑色素瘤病例中,CDKN2A突变是关键.
- 瘤透淋巴细胞 (TILs),特别是CD8阳性T细胞,影响黑色素瘤的存活率.
研究的目的:
- 为了比较手动"裸眼"计数CD8阳性T细胞的准确性与人工智能辅助的软件来定量CD8阳性TILs在黑色素瘤中.
- 调查CD8阳性TIL在家族性和多重原发性黑色素瘤的预后意义.
主要方法:
- 对23名黑色素瘤患者 (2018-2022) 进行了回顾性横截面研究,这些患者有家族病史或多重原发性病变.
- 组织病理学诊断,CDKN2A突变分析 (光在位杂交) 和CD8免疫组织化学.
- 手动 (肉眼) 和自动 (QuPath AI软件) 量化CD8阳性TILs.
主要成果:
- 与手动评估相比,人工智能介导的软件可以更准确地识别CD8阳性TIL.
- 较高的内CD8阳性淋巴细胞与 stromal 淋巴细胞的百分比与更多的转移部位有关.
- CD8表型在家族性和多重原发性黑色素瘤中具有重要意义.
结论:
- 人工智能软件提供了一种更精确的方法来量化黑色素瘤中CD8阳性TILs.
- CD8阳性TIL是家族性和多重原发性黑色素瘤的显著预后指标.
- 这种方法可能为黑色素瘤的预后和预测免疫疗法反应提供一种具有成本效益的方法.
关键词:
CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD9 CD8 CD8 CD8 CD9 CD8 CD9 CD8 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 是一个字体的字体的字体是什么意思这是一种CDKN2A突变.这是家族性黑色素瘤.免疫组织化学 免疫组织化学多重原发性黑色素瘤是一种多重的原发性黑色素瘤.相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Cancers Originate from Somatic Mutations in a Single Cell
12.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.0K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


